antioxidant capacity in fibromyalgia

What is it about?

Recent studies suggested a possible role of high levels of plasma lysophosphocholines (lysoPCs) and their possible role in Fibromyalgia Syndrome (FMS). Aim of the study was to evaluate the content of plasma phospholipase s (e.g. Platelet Activating Factor Acetyl Hydrolase (PAF-AH); secretory Phospholipase A2 (sPLA2), Total Antioxidant Capacity (TAOC) and 2,7,8-trimethyl-2-(2-carboxyethyl)-6-hydroxy chroman (γ-CEHC) in FMS patients and their association with clinical status and quality of life.

Featured Image

Why is it important?

Higher levels of sPLA2 and lower of PAF-AH and γ-CEHC were observed in the plasma of FMS patients compared to the controls. A decrease in PAF-AH and Total Antioxidant Capacity (TAOC) levels was found in severe FMS (S-FMS) compared to to mild/slight (MS-FMS) forms. The results of the study indicate a possible involvement of phospholipases and γ-CEHC in fibromyalgia syndrome.